Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/pin.12455 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
Gynecol Oncol
March 2025
Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115, United States of America. Electronic address:
Background: There are limited data around adjuvant radiotherapy following surgical management for patients with early-stage uterine carcinosarcoma (UCS). We compared outcomes for patients with early-stage UCS who underwent adjuvant chemotherapy (CT) and pelvic external beam radiotherapy (EBRT) vs. CT and vaginal brachytherapy (VBT) vs.
View Article and Find Full Text PDFUpdates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma.
Int J Gynecol Cancer
January 2025
Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Johns Hopkins University, Baltimore, MD, USA. Electronic address:
Uterine serous carcinoma and uterine carcinosarcoma are among the rarest but most lethal endometrial cancer sub-types, accounting for 15% of all cases, and are responsible for more than 50% of related deaths. These malignancies are distinguished by a high likelihood of metastasis and multisite recurrence, making them biologically different from other endometrial cancer sub-types. This review aims to analyze the existing evidence regarding molecular classification, new biomarkers, and innovative treatment approaches for these high-risk tumors.
View Article and Find Full Text PDFUterine carcinosarcoma with heterologous osseous elements: a case report of an extremely rare clinical occurrence with literature review.
Front Oncol
February 2025
Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, United States.
Carcinosarcoma is a rare and aggressive malignant neoplasm that predominantly affects elderly postmenopausal women and can involve various gynecologic organs. It is characterized by the presence of both malignant epithelial and sarcomatous components. While most uterine carcinosarcomas (UCS) are homologous (sarcomatous component consisting of elements native to the uterus), heterologous components are less common and may vary in composition.
View Article and Find Full Text PDFHDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer.
Clin Epigenetics
February 2025
Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
Breast cancer has constantly been the leading causes of death in women, and hormone receptor (HR) positive, HER2 negative is the majority subtype. Histone deacetylase (HDAC) inhibitors (HDACi) have shown clinical benefit in HR ( +) breast cancer patients. The Hippo pathway is an important cellular pathway involving proliferation, cell contact, and cancer.
View Article and Find Full Text PDFUterine Carcinosarcoma-A Retrospective Cohort Analysis from a Tertiary Centre on Epidemiology, Management Approach, Outcomes and Survival Patterns.
Cancers (Basel)
February 2025
Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Background/objectives: Uterine carcinosarcoma (UCS) refers to a rare high-grade aggressive epithelial non-endometrioid endometrial carcinoma, with tumour cells demonstrating epithelial-mesenchymal metaplastic transition and composed of both carcinomatous epithelial and sarcomatous (homologous or heterologous) components.
Methods: The aim of this study was to evaluate the epidemiology, management approach, outcomes and survival patterns of patients with UCS. Seventy-seven cases of UCS treated with primary surgery in a single tertiary centre underwent retrospective cohort analysis across a ten-year period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!